Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have received an average recommendation of “Hold” from the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $28.70.
A number of analysts recently issued reports on the company. TD Cowen cut their price objective on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Barclays raised their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 11th. Bank of America cut their price objective on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th.
Read Our Latest Research Report on HIMS
Hims & Hers Health Stock Up 2.9%
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the business earned $0.20 earnings per share. As a group, equities analysts forecast that Hims & Hers Health will post 0.04 EPS for the current year.
Insiders Place Their Bets
In related news, insider Soleil Boughton sold 9,463 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. This trade represents a 3.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,950 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $23.64, for a total value of $187,938.00. Following the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at $6,216,232.56. The trade was a 2.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 212,807 shares of company stock valued at $5,473,644 over the last 90 days. Company insiders own 11.76% of the company’s stock.
Hedge Funds Weigh In On Hims & Hers Health
Several institutional investors have recently bought and sold shares of the company. Avidity Partners Management LP acquired a new position in Hims & Hers Health in the 1st quarter valued at about $1,557,000. Western Wealth Management LLC acquired a new position in Hims & Hers Health in the 1st quarter valued at about $166,000. Bank of America Corp DE grew its position in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Sunbelt Securities Inc. grew its position in Hims & Hers Health by 5,444.7% in the 1st quarter. Sunbelt Securities Inc. now owns 23,565 shares of the company’s stock valued at $489,000 after acquiring an additional 23,140 shares in the last quarter. Finally, Amundi grew its position in Hims & Hers Health by 94.1% in the 1st quarter. Amundi now owns 20,371 shares of the company’s stock valued at $423,000 after acquiring an additional 9,876 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.
About Hims & Hers Health
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
